Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SRRA Sierra Oncology (SRRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Sierra Oncology Stock (NASDAQ:SRRA) 30 days 90 days 365 days Advanced Chart Ad Desko DigitalCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Get Sierra Oncology alerts:Sign Up Key Stats Today's Range$54.99▼$54.9950-Day Range$54.73▼$54.9952-Week Range$14.91▼$55.19VolumeN/AAverage Volume931,731 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Read More… Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Receive SRRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address SRRA Stock News HeadlinesSierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Oncology Inc.February 21, 2024 | thestreet.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Sierra Coupon for OctoberNovember 9, 2023 | time.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaSeptember 18, 2023 | msn.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 16, 2023 | proactiveinvestors.comSee More Headlines SRRA Stock Analysis - Frequently Asked Questions How were Sierra Oncology's earnings last quarter? Sierra Oncology, Inc. (NASDAQ:SRRA) posted its earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/05/2021Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone(604) 558-6536FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.88% Return on Assets-100.01% Debt Debt-to-Equity Ratio0.02 Current Ratio21.27 Quick Ratio21.27 Sales & Book Value Annual Sales$300,000.00 Price / Sales4,476.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book8.93Miscellaneous Outstanding Shares24,419,000Free Float13,650,000Market Cap$1.34 billion OptionableOptionable Beta0.03 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:SRRA) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sierra Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.